Advanced chronic myelomonocytic leukemia in elderly and frail patients managed by azacitidine in the field of clinical practice

Advanced chronic myelomonocytic leukemia in elderly and frail patients managed by azacitidine in... Ann Hematol (2017) 96:1591–1593 DOI 10.1007/s00277-017-3064-0 LETTER TO THE EDITOR Advanced chronic myelomonocytic leukemia in elderly and frail patients managed by azacitidine in the field of clinical practice 1 1 1 1 Pasquale Niscola & Andrea Tendas & Elisabetta Abruzzese & Tommaso Caravita & 1 1 1 1 Luca Cupelli & Marco Giovannini & Laura Scaramucci & Agostina Siniscalchi & 1 1 Monika Malgorzata Trawinska & Paolo de Fabritiis Received: 3 June 2017 /Accepted: 4 July 2017 /Published online: 12 July 2017 Springer-Verlag GmbH Germany 2017 Dear Editor, for the role of azacitidine in the CMML management, Chronic myelomonocytic leukemia (CMML) is an despite an overall response rate (ORR) and median aging-related clonal hematopoietic stem cell disorder, overall survival (OS) ranging from 39 to 60% and from classified as myelodysplastic/myeloproliferative disor- 12 to 37 months respectively reported by some studies ders [1]. Indeed, its disease phenotype usually combines [4–7] outside clinical trials, a matched-pair analyses of myelodysplastic (MD) and myeloproliferative (MP) fea- real-life CMML patients showed that this epigenetic tures. Therefore, other than a persistent peripheral agent do not modify the natural course of the disease monocytosis representing the hematological disease hall- [5]. Therefore, with the exception of patients http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Hematology Springer Journals

Advanced chronic myelomonocytic leukemia in elderly and frail patients managed by azacitidine in the field of clinical practice

Loading next page...
 
/lp/springer_journal/advanced-chronic-myelomonocytic-leukemia-in-elderly-and-frail-patients-0iMyL2MUR7
Publisher
Springer Berlin Heidelberg
Copyright
Copyright © 2017 by Springer-Verlag GmbH Germany
Subject
Medicine & Public Health; Hematology; Oncology
ISSN
0939-5555
eISSN
1432-0584
D.O.I.
10.1007/s00277-017-3064-0
Publisher site
See Article on Publisher Site

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial